Majid Mohammad Shafiee | Regulatory Affairs | Research Excellence Award

Published on by Top Pharmaceutical

Dr. Majid Mohammad Shafiee | Regulatory Affairs | Research Excellence Award

University of Isfahan | Iran

Dr. Majid Mohammad Shafiee is an Associate Professor in the Department of Management at the University of Isfahan and a distinguished scholar in the fields of marketing, competition, tourism, consumer behavior, and brand management. He has authored several scholarly books and published extensively in high-impact international journals indexed in SCI and Scopus, contributing significantly to theoretical and applied business research. His academic work is widely cited, reflecting strong research influence across interdisciplinary domains. Dr. Shafiee actively serves as a reviewer for leading peer-reviewed journals and holds editorial and scientific committee roles within professional associations. In parallel with his academic achievements, he has led and supervised numerous research and consultancy projects for industry partners, translating scientific insight into practical solutions. His international research collaborations further enhance the global relevance and impact of his scholarly contributions.

Citation Metrics (Scopus)

700

500

300

100

0

Citations
641

Documents
38

h-index
14


View Scopus Profile
 View Google Scholar Profile

Featured Publications

Ruby Anto | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Ruby Anto | Drug Discovery and Development | Best Researcher Award

Centre of Excellence in Nutraceuticals | India

Dr. Ruby Anto is a distinguished biochemist and cancer researcher with an extensive career dedicated to advancing the fields of molecular oncology, bioimmunotherapy, and nutraceutical science. She currently serves as Chief Scientist at the Centre of Excellence in Nutraceuticals, KSCSTE, Government of Kerala, Thiruvananthapuram, and Honorary Scientist at the Institute of Advanced Virology, Thiruvananthapuram. Over her accomplished career, she has held numerous scientific positions at the Rajiv Gandhi Centre for Biotechnology, progressing from Research Associate to Scientist G, reflecting her consistent contributions and leadership in biomedical research.Dr. Anto earned her PhD in Biochemistry from Amala Cancer Research Centre, Thrissur, following her postgraduate studies in Chemistry and Education. Her multidisciplinary academic background—combining chemistry, biochemistry, and pedagogy—has been central to her innovative approach to cancer biology and molecular medicine. Her early academic achievements and later professional experiences at prestigious institutions such as the M.D. Anderson Cancer Center, Houston, provided a strong foundation for her research on targeted cancer therapies, chemopreventive agents, and the role of natural products in disease modulation.Recognized nationally and internationally for her scientific excellence, Dr. Anto has received several prestigious honors, including the Young National Women Bio-Scientist Award from the Department of Biotechnology, Government of India, and fellowships from the National Academy of Sciences, India, and the Academy of Sciences, Thiruvananthapuram. Her professional journey also includes global training experiences, such as her participation in the Clinical Trials Traineeship Program at INSERM, Paris, which broadened her expertise in translational research and clinical validation of nutraceutical interventions.As a mentor, Dr. Anto has nurtured a generation of young scientists, with her students and postdoctoral fellows earning numerous national and international awards for their work in cancer biology and nutraceutical research. Her leadership has fostered a thriving academic environment focused on the discovery and characterization of bioactive compounds from natural sources with therapeutic potential.Dr. Anto’s scientific publications have advanced understanding in areas such as natural compound-mediated cancer prevention, signaling pathway modulation, and anti-inflammatory mechanisms of nutraceuticals. Through her research, she continues to bridge the gap between basic biochemistry and applied health sciences, promoting nutraceutical innovation as a cornerstone of preventive and personalized medicine. Her lifelong dedication to scientific inquiry and mentorship underscores her status as one of India’s leading voices in biochemistry and nutraceutical research.

Profile: Google Scholar

Featured Publications

Ruby, A. J., Kuttan, G., Babu, K. D., Rajasekharan, K. N., & Kuttan, R. (1995). Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Letters, 94(1), 79–83.

Anto, R. J., Mukhopadhyay, A., Denning, K., & Aggarwal, B. B. (2002). Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: Its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis, 23(1), 143–150.

Anto, R. J., Sukumaran, K., Kuttan, G., Rao, M. N. A., Subbaraju, V., & Kuttan, R. (1995). Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Letters, 97(1), 33–37.

Oommen, S., Anto, R. J., Srinivas, G., & Karunagaran, D. (2004). Allicin (from garlic) induces caspase-mediated apoptosis in cancer cells. European Journal of Pharmacology, 485(1–3), 97–103.*

Anto, R. J., Mukhopadhyay, A., Shishodia, S., Gairola, C. G., & Aggarwal, B. B. (2002). Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of IκBα: Correlation with induction of cyclooxygenase-2. Carcinogenesis, 23(9), 1511–1518.*

Bava, S. V., Puliappadamba, V. T., Deepti, A., Nair, A., Karunagaran, D., & Anto, R. J. (2005). Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. Journal of Biological Chemistry, 280(8), 6301–6308.*

Srinivas, G., Anto, R. J., Srinivas, P., Vidhyalakshmi, S., Senan, V. P., & Karunagaran, D. (2003). Emodin induces apoptosis of human cervical cancer cells through poly (ADP-ribose) polymerase cleavage and activation of caspase-9. European Journal of Pharmacology, 473(2–3), 117–125.*

Hejian Zou | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Hejian Zou | Clinical Trials | Best Researcher Award

Dr. Hejian Zou at Huashan Hospital, Fudan University, China.

Dr. Hejian Zou is a renowned physician-scientist in the fields of rheumatology and immunology, with over three decades of academic and clinical experience. He earned his medical degree from Shanghai Medical University and steadily rose through the academic ranks, becoming a professor in 2003. A prolific researcher and clinician, he has led numerous national research projects focusing on autoimmune mechanisms, macrophage polarization, and innovative therapies for gout and arthritis. He has published extensively in high-impact journals and holds multiple patents. Dr. Zou has also authored influential books and serves on editorial boards of several prominent medical journals. He plays a critical leadership role at Huashan Hospital, Fudan University, and in several major national and international professional associations. Through his pioneering research, teaching, and clinical innovations, Dr. Zou has significantly advanced the understanding and treatment of autoimmune and connective tissue diseases in China and beyond.

Publication Profile 

Orcid

Education

Professor Hejian Zou began his academic journey at Shanghai Medical University, graduating in 1987 with a six-year degree in medical sciences. He continued at the same institution, earning a Doctor of Medicine degree in 1992 from the university’s prestigious graduate school. His educational path laid a strong foundation in both theoretical and clinical medicine, especially in immunology and rheumatology. Throughout his medical training, he demonstrated a profound interest in chronic inflammatory diseases, which later became his central research focus. His academic accomplishments led to successive promotions: he became an associate professor in 1994, a chief physician in 1999, and achieved the rank of full professor in 2003. His academic pedigree and continuous involvement in both teaching and research reflect a lifelong dedication to medical education, innovation, and mentoring the next generation of physicians and researchers in the field of autoimmune disorders and connective tissue diseases.

Experience

Professor Zou has built a distinguished career marked by excellence in clinical medicine, academic leadership, and scientific research. He currently serves as a professor and head of rheumatology and immunology at Huashan Hospital, Fudan University, one of China’s premier medical institutions. Over the years, he has led several national research projects, including studies on macrophage polarization in gout, follicular helper T cells in SLE, and T regulatory cell therapy for arthritis. With a citation index exceeding 2600, his publications have influenced both Chinese and global rheumatology. He has actively contributed to medical education, mentoring students and young researchers. In parallel, Dr. Zou has worked on translational research, holding patents for novel gout therapies. His role extends to editorial and advisory positions in key medical journals and organizations. His comprehensive expertise and commitment have established him as a leading voice in rheumatology across clinical, academic, and scientific communities.

Awards 

Professor Hejian Zou’s pioneering work has earned him numerous accolades in the field of rheumatology and immunology. He has been a recipient of national research funding awards for his studies on autoimmune diseases, including three major projects under the National Natural Science Foundation of China. He has also received multiple patents for his discoveries in gout therapies, showcasing his commitment to translational and impactful research. Professor Zou is a Vice Chairman of The International Network of Scleroderma Clinical Care and Research (InSCAR) and holds top roles in major Chinese medical associations. His inclusion in editorial boards of renowned journals like the Journal of Chinese Rheumatology and Practical Internal Medicine further reflects his scientific stature. Recognized for both clinical excellence and research, Dr. Zou is a frequent speaker at international conferences, representing China on the global rheumatology stage. His achievements continue to inspire emerging researchers and clinicians worldwide.

Research Focus 

Professor Hejian Zou’s research focuses on autoimmune and connective tissue diseases, with a strong emphasis on gout, systemic lupus erythematosus (SLE), and rheumatoid arthritis. He explores the cellular and molecular mechanisms behind chronic inflammation and immune dysregulation, particularly macrophage polarization, regulatory T cell therapy, and follicular helper T cell function. His projects aim to develop targeted therapies that improve patient outcomes in autoimmune conditions. A pioneer in translational medicine, he has patented natural and pharmacological agents—such as paeoniflorin and melatonin—for the treatment of gout. His approach combines basic immunology, experimental therapeutics, and clinical trials, enabling bench-to-bedside innovation. He actively collaborates with national institutions, mentors young scientists, and publishes widely in SCI-indexed journals. His lab’s work not only contributes to the understanding of autoimmune pathogenesis but also to drug development and personalized treatment strategies for chronic inflammatory diseases.

Publication Top Notes

  • Spatial multiomics decipher fibroblast–macrophage dynamics in systemic sclerosis

  • A Common Functional Variant at the Enhancer of the Rheumatoid Arthritis Risk Gene ORMDL3 Regulates its Expression Through Allele-Specific JunD Binding

Rahul K. Reddy – Pharmacology – Excellence in Research

Published on by Top Pharmaceutical

Rahul K. Reddy - Pharmacology - Excellence in Research

Lautoka Hospital - Fiji

Introduction

Rahul K. Reddy is an accomplished researcher and medical professional specializing in urology, surgery, and trauma care. With a focus on advancing medical understanding and clinical outcomes in challenging cases, Dr. Reddy has contributed significantly to the fields of laparoscopic surgery, burn care, and acute surgical conditions. His work is characterized by its depth of clinical insight and dedication to improving patient outcomes in diverse healthcare settings, particularly in Fiji.

Laparoscopic Surgery in Urology

Dr. Reddy's pioneering work in the laparoscopic excision of seminal vesicle cystadenoma underscores his expertise in minimally invasive surgical techniques. Published in Urology Case Reports (2019), this study has provided valuable insights into rare urological conditions, offering innovative approaches to their management.

Burn Injury Characteristics and Outcomes

In collaboration with a multidisciplinary team, Dr. Reddy conducted an in-depth analysis of burn injury patterns and treatment outcomes at Lautoka Hospital. His findings, featured in Burns Open (2024), have contributed to the optimization of burn care protocols in resource-limited settings, enhancing recovery rates and patient care quality.

Acute Appendicitis Management

Through an observational retrospective study on acute appendicitis at Lautoka Aspen Hospital, Dr. Reddy explored the clinical characteristics and outcomes over a one-year period (2022–2023). Published in World Journal of Surgical Research (2024), this research offers evidence-based recommendations for improving appendicitis management in Pacific Island healthcare systems.

Rare Tumors and Pathologies

Dr. Reddy has also delved into the study of rare pathologies, such as primary epithelioid hemangioendothelioma of the kidney pelvis. His case report, published in the American Journal of Surgery and Clinical Case Reports (2020), adds to the limited literature on this rare tumor type, emphasizing the importance of early diagnosis and tailored surgical interventions.

Trauma and Emergency Medicine

With a holistic approach to trauma care, Dr. Reddy's research addresses the critical needs of patients in emergency settings. His work highlights the significance of multidisciplinary collaboration and protocol-driven management in achieving favorable outcomes for complex trauma cases.

Conclusion

Rahul K. Reddy’s extensive research portfolio reflects his unwavering commitment to advancing medical science and improving patient care. By addressing diverse challenges in urology, surgery, and trauma care, Dr. Reddy continues to contribute to the development of innovative treatments and clinical best practices, with a lasting impact on global and regional healthcare.

NOTABLE PUBLICATION

Laparoscopic excision of seminal vesicle cystadenoma 2019 (4)

Burns injury characteristics and outcomes at lautoka hospital, fiji 2024

Characteristics and Outcomes of Acute Appendicitis in Lautoka Aspen Hospital, Fiji: An Observational Retrospective Study (09/22–09/23) 2024

Primary Epithelioid Hemangioendothelioma of the Kidney Pelvis 2020